Pharmacokinetic and organ distribution studies of liposomal drugs in humans are a challenge. A direct labeling method using 99m
ance with half-clearance times of 2.2 and 26.2 h after bolus intravenous injection in normal rats. Distribution of 99m Tc-Doxil at 44 h after injection had 19.8 Ϯ 1.3% of injected dose in blood, 14.1 Ϯ 1.7% in liver, 2.6 Ϯ 0.3% in spleen, 9.0 Ϯ 0.8% in bone with marrow, 6.0 Ϯ 0.5% in skin, and 15.3 Ϯ 4.3% in bowel (n ϭ 5). Unencapsulated 99m Tc-BMEDA had a very rapid blood clearance with a half-clearance time of only 0.12 h (n ϭ 4). By using this 99m Tc labeling method, biodistribution and pharmacokinetics of ammonium gradient liposomes encapsulating drugs can be determined by noninvasive scintigraphic imaging. This labeling method may be extended to 186 Re and 188 Re labeling to combine chemotherapy and radionuclide therapy for tumor treatment.
Transmembrane pH or ammonium gradient liposomes are promising drug carriers, because these liposome formulations can achieve high drug encapsulation capacity and high drug entrapment efficiency (Mayer et al., 1986 (Mayer et al., , 1990 Haran et al., 1993) . Pegylated liposomes have prolonged residence time in blood, resulting in greater treatment effectiveness and lower treatment complications (Gabizon et al., 2003) . Doxil, a commercially available pegylated liposomal doxorubicin, uses an ammonium gradient to load and carry doxorubicin for clinical tumor treatment (Gabizon et al., 2003) . Animal and human subject studies have been performed with Doxil to treat various kinds of tumors (Gabizon, 1992; Harrington et al., 2000b) . Because it is necessary to know the in vivo behavior of the therapeutic drugs trapped in liposomes as well as the free drugs after liposomal therapeutic drug administration, the pharmacokinetic study of liposomal therapeutic drugs tends to be more complex than routine drugs (Harashima et al., 2002) .
Several ␥-emitting radionuclides can be used to label liposomes for monitoring the in vivo behavior of liposomes noninvasively (Harrington et al., 2000a,b) . By using imaging systems, such as a gamma camera or a positron emission tomography camera, the whole body distribution of a radiolabeled carrier or a radiolabeled compound in each organ or tissue can be measured at different times in a live animal or in a human subject. By using noninvasive imaging, fewer animals are required to study the pharmacokinetics of drugs, making it more efficient and usually cheaper to perform the studies (Contag, 2002) . In addition, increased statistical significance can be reached with fewer animals, because the images of each animal acquired at the initial time point can serve as the internal control at subsequent time points. Positron emission radionuclides, such as carbon-11 ( 11 C), nitrogen-13 ( 13 N), and fluorine-18 ( 18 F), may be used to label drug or carrier molecules (Aboagye et al., 2001) . The disadvantage of these positron emission tomography radionuclides is that they have relatively short half-lives ( 11 C, 20.4 min; 13 N, 10.0 min; and 18 F, 109.8 min), which makes it harder to trace the in vivo behavior of a drug or a carrier for long time periods.
Another group of radionuclides are single photon emitters, such as technetium-99m ( 99m Tc) and indium-111 ( 111 In).
These single photon emission radionuclides have longer halflives ( 99m Tc, 6.007 h; 111 In, 2.80 days), permitting the monitoring of the in vivo distributions of 99m Tc and 111 In labeled compounds for longer period using a gamma camera, which is readily available equipment in a nuclear medicine department. Liposome radiolabeling methods with 99m Tc, 111 In, or 67 Ga have been described (Kassis and Taube, 1987; Essien and Hwang, 1988; Phillips et al., 1992; Woodle, 1993; Laverman et al., 1999) . These labeling processes attach radioisotopes to the surface of a liposome or trap radioisotopes in the liposome inner space. For surface labeling, a coordinate ligand needs to be attached to lipid or cholesterol molecules to bind the radioisotopes to a liposome by forming complexes with those metallic radioisotopes. Use of these surface labeling methods makes the radiolabeled liposomes structurally different from the actual liposomal therapeutic drugs used clinically. These surface modifications can potentially change the in vivo behavior of the liposomes, and it may be argued as to whether these surface-altered liposomes can represent the clinically used liposomal therapeutic drugs.
In labeling radioisotopes to the inner space of a liposome by using a remote loading technique, a chemical gradient between the inner space and outer space needs to be constructed to induce high-efficiency encapsulation and stable entrapment. One of the most frequently used 99m Tc-liposome labeling methods applied to liposome studies uses glutathione pre-encapsulated liposomes and 99m Tc-hexamethyl propyleneamine oxime (Phillips et al., 1992; Tilcock, 1999) . To study the in vivo behavior of pH or ammonium gradient liposomes trapping drug molecules, an ideal approach would be the labeling of radioisotopes directly into the inner space of liposomes via pH or ammonium gradient mechanism. No previous study has been reported as using a direct labeling method to label pH or ammonium gradient liposomes with 99m Tc. In this paper, we report a direct 99m Tc labeling method to label a commercially available pegylated liposomal doxorubicin, Doxil, using 99m Tc-SNS/S N,N-bis(2-mercaptoethyl)-NЈ,NЈ-diethyl-ethylenediamine (BMEDA) (Fig. 1) . The in vitro labeling stability of 99m Tc-Doxil using this labeling method was studied by incubating it in 50% serum at 37°C. The normal rat distribution of 99m Tc-Doxil was also studied to assess the potential of using 99m Tc labeling to study the pharmacokinetics and organ distribution of liposomes encapsulating drug molecules.
Materials and Methods
Materials. Doxil, a commercial product of ALZA Corporation and manufactured by Ben Venue Laboratories, Inc. (Bedford, OH), was purchased from the University of Texas hospital pharmacy (San Antonio, TX). Doxil has an average particle size of 87.3 Ϯ 8.5 nm before radiolabeling, determined using 488-nm laser light scattering (Dynamic Light Scattering; Brookhaven Instruments, Holtsville, NY). It contains 2 mg/ml of doxorubicin, 3.19 mg/ml of N-(carbonylmethoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt, 9.58 mg/ml of fully hydrogenated soy phosphatidylcholine, and 3.19 mg/ml of cholesterol. BMEDA was synthesized from a modification of the method by Corbin et al. (1984) , and the chemical structures were verified with 1 H and 13 C NMR.
99m Tc-pertechnetate was purchased from Amersham Health Nuclear Pharmacy (San Antonio, TX). Glucoheptonate (GH) (SigmaAldrich, St Louis, MO) was used as an intermediate ligand to make 99m Tc-BMEDA. Stannous chloride (Aldrich Chemical Co., Milwaukee, WI) was used as the reductant to make 99m Tc-GH. Fetal bovine serum (FBS) was purchased from Invitrogen (Carlsbad, CA). Human blood was donated by a volunteer. After the fresh human blood was centrifuged at 4000 rpm for 10 min, the serum was removed to a separate tube and aliquoted for in vitro stability study. Bio-Gel A-15m gel was purchased from Bio-Rad (Hercules, CA).
99m Tc-Doxil Preparation. A two-step method was used to prepare 99m Tc-BMEDA. In the first step, 99m Tc-sodium pertechnetate was reduced by stannous chloride, and the reduced 99m Tc(V) formed a complex with GH. In the second step, BMEDA was added to 99m Tc-GH solution, and 99m Tc-BMEDA was formed via ligand exchange mechanism.
The preparation of 99m Tc-GH and 99m Tc-BMEDA was as described previously with minor modifications (Bao et al., 2003a) . In brief, 99m Tc-GH was prepared in-house by pipetting 1.0 ml of freshly made degassed GH (10 mg/ml) solution (pH 7.0) containing 0.16 mg/ml SnCl 2 into a vial. Then, 99m Tc-sodium pertechnetate [45 mCi (1.665 GBq)] in 0.50 ml of saline was added. The mixture was stirred at 25°C for 20 min. The labeling efficiency of the 99m Tc-GH was checked by paper chromatography eluted in methanol and paper chromatography eluted in saline.
BMEDA [3.5 l (ϳ3.9 mg)] was moved to a new vial. Then, 5.0 ml of degassed water and 4 drops of 0.05 M NaOH were added. The solution was stirred at 25°C for 40 min. After preparation, the BMEDA solution was labeled with 99m Tc by adding 1.0 ml of BMEDA solution to 0.50 ml of 99m Tc-GH [15 mCi (555 MBq)]. After adjusting the pH to 8.0, the mixture was stirred at 25°C for 25 min. The labeling efficiency of the 99m Tc-BMEDA was determined using paper chromatography eluted in methanol and paper chromatography eluted in saline. The labeling efficiency for 99m Tc-BMEDA was greater than 85%. The average particle size of Doxil after 99m Tc labeling was measured using 488-nm laser light scattering. The resultant 99m Tc-BMEDA was used for liposome labeling without further purification.
The 99m Tc labeling protocol of Doxil for labeling efficiency and in vitro stability study is as follows. Doxil (0.5 ml) was added to the 99m Tc-BMEDA [15 mCi (555 MBq)] solution prepared as above. The mixture was vortexed for 1 min and kept at 25°C for 1 h. The 99m Tc-Doxil was separated from free 99m Tc-BMEDA using Sephadex G-25 column chromatography eluted with PBS buffer, pH 7.4. The red color of Doxil was used to visually monitor the collection of the 99m Tc-Doxil. The labeling efficiency was calculated by using the activity in Doxil after separation divided by the total activity before separation.
The 99m Tc labeling of Doxil for the rat distribution study was similar to the procedure described above except that 6 ml of Doxil was labeled with 10 mCi (370 MBq) of 99m Tc-BMEDA to meet the amount of Doxil needed for injection at the clinical dosage. The labeled Doxil solution was aliquoted into four parts, and four Sephadex G-25 columns were used to separate each aliquot to remove the 99m Tc-BMEDA. The four eluted 99m Tc-Doxil aliquots were pooled and used for the rat distribution study.
99m Tc-Doxil In Vitro Labeling Stability. An aliquot of 99m TcDoxil after column chromatography separation was added to an aliquot of FBS (Invitrogen) or human serum in a 1:1 volume ratio and incubated at 37°C. The amount of 99m Tc activity associated with Doxil at different times was measured using Bio-Gel A-15m Gel (Bio-Rad) spin column (Chonn et al., 1991) . Bio-Gel A-15m gel (2.0 ml) was packed in a microcolumn (Bio-Rad) by centrifugation at 1000 rpm for 2 min. Then, 10 column volumes of PBS buffer, pH 7.4, were used to remove any ethanol and equilibrate column. At various times of incubation, 50 l of 99m Tc-Doxil serum solution was added to an equilibrated spin column, the column was centrifuged at 1000 rpm for 1 min, and the first fraction was collected in a tube. Then, 100 l of PBS buffer, pH 7.4, was added to the column and centrifuged at 1000 rpm for 1 min, and the second fraction was collected in a new tube. The elution process using 100 l of PBS buffer, pH 7.4, was repeated 19 times, and each fraction was collected after the centrifugation. The 99m Tc activity in each fraction was counted using a Minaxi␥ A5550 gamma counter (PerkinElmer Life and Analytical Sciences, Boston, MA). The percentage of 99m Tc activity associated with Doxil was calculated by summing the total 99m Tc activity in the first 6 fractions divided by the total 99m Tc activity of all 20 fractions. The relative doxorubicin concentration in each fraction was measured spectrophotometrically by mixing an aliquot (50 l) of each fraction with 700 l of methanol (EM Scientific, Gibbstown, NJ) in a 1-ml cuvette. The absorbance was measured at 450 nm (Iden and Allen, 2001 ). The protein concentration in each fraction was determined using Micro BCA protein assay reagent kit (Pierce Endogen, Rockford, IL). The remaining 99m Tc activities in the spin columns after 20 fractions were less than 5%.
Normal Rat Distribution of 99m Tc-Doxil. To directly compare 99m Tc-Doxil with 99m Tc-BMEDA, normal rat distributions were performed simultaneously. The animal experiments were performed according to the National Institutes of Health Animal Use and Care Guidelines and were approved by our Institutional Animal Care Committee. Normal Sprague-Dawley male rats (309 g on average) were anesthetized by inhalation with isoflurane (VEDCO, Inc., St. Joseph, MO) (3% in 100% oxygen). The 99m Tc-Doxil (2.0 ml) containing 0.45 mCi (16.65 MBq) of 99m Tc, 2 mg of doxorubicin (6.47 mg doxorubicin/kg rat), and 15.96 mg of total lipids or 2.0 ml of free 99m Tc-BMEDA containing 0.45 mCi (16.65 MBq) of 99m Tc was administered to each rat by bolus injection through tail vein. Blood samples (50 l per sample) were collected from the tail vein opposite to the administration vein at baseline, 30 min, and 2, 4, 20, and 44 h after administration. The gamma camera images were acquired at the times immediately after blood collection (image resolution, 128 ϫ 128; acquisition time, 1 min each from baseline to 4 h after administration, 5 min at 20 h, and 20 min at 44 h).
After blood sample collection and image acquisition at 44 h, anesthetized rats were euthanized by cervical dislocation, and the major organs and tissues were collected. Femur with bone marrow was taken as representative of bone and bone marrow. Accumulated bowel or feces activity in 44 h was determined by counting an aliquot of samples after digestion in saturated NaOH. The 99m Tc activity distribution of 99m Tc-Doxil or free 99m Tc-BMEDA in various rat tissues and the blood samples collected from the tail veins at various times were measured with a Minaxi␥ A5550 gamma counter (PerkinElmer Life and Analytical Sciences). Total blood, bone, muscle, and skin mass of rats were calculated as 5.4, 10, 40, and 13% of total body weight, respectively (Frank, 1976) . No blood correction was performed with organ activity. The blood clearance pattern of 99m Tc-Doxil or free 99m Tc-BMEDA was simulated with the following dual-exponential equation:
Here Y is the percentage of blood 99m Tc activity; t is the time after injection; b 1 , b 2 , c 1 , and c 2 are constants. The two-phase blood clearance half-times [(t 1/2 ) 1 and (t 1/2 ) 2 ] were calculated from the simulated dual-exponential curves as follows: (t 1/2 ) 1 ϭ 0.693/c 1 ; (t 1/2 ) 2 ϭ 0.693/c 2 .
Statistical Analysis. MiniTab (MiniTab Inc., State College, PA) was used to perform statistical analysis. Origin software (OriginLab Corp., Northampton, MA) was used to simulate blood clearance patterns and spin column data. All average values are given as mean Ϯ S.D. The comparison of percentage of injected dose per organ between 99m Tc-Doxil and free 99m Tc-BMEDA groups was determined using one-way analysis of variance. The acceptable probability for a significant difference was P Ͻ 0.05.
Results

Labeling Efficiency of
99m Tc-Doxil. The labeling efficiency of 99m Tc-Doxil for in vitro stability studies was 70.6 Ϯ 0.8% (n ϭ 3). The labeling efficiency of 99m Tc-Doxil for rat distribution study was 39.5%. After 99m Tc labeling, the average particle size of Doxil was 89.9 Ϯ 16.2 nm, which is similar to the particle sizes of Doxil before 99m Tc labeling. In Vitro Labeling Stability of 99m Tc-Doxil. The spin column elution profiles of 99m Tc activity, doxorubicin, and serum protein are shown in Fig. 2 . Doxorubicin was in red color. After the 6th fraction of spin column elution, no doxorubicin was observed. Spectrophotometric measurements of fractions after the 6th fraction of elution were at background levels. Assuming 99m Tc activity was associated with the liposomes trapping doxorubicin or with the serum protein at different times of incubation, the simulated curve of 99m Tc activity of the sample after incubation for 72 h is shown in Fig. 2 . The simulated curve showed very good correlation with the 99m Tc activity profile. This suggests that 99m Tc release from liposomes was mediated by serum protein.
The percentage of 99m Tc associated with liposomes after incubation in 50% FBS-PBS buffer, pH 7.4, at 37°C at different times is shown in Fig. 3 . After a 24-h incubation, there was 72.3 Ϯ 3.6% of 99m Tc activity associated with liposomes. Incubation of 99m Tc-Doxil in 50% human serum-PBS buffer, pH 7.4, at 37°C showed that 78.6 Ϯ 1.8% of 99m Tc activity associated with Doxil at 24 h and 77.9 Ϯ 0.5% associated with Doxil at 72 h (n ϭ 3). After storing 99m Tc-Doxil at 25°C in PBS buffer, pH 7.4, for 24 h, there was 89.4 Ϯ 0.55% of 99m Tc activity associated with liposomes.
Normal Rat Distribution of 99m Tc-Doxil. The gamma camera images of 99m Tc-Doxil labeled with 99m Tc-BMEDA and 99m Tc-BMEDA alone after intravenous bolus injection at various times are shown in Fig. 4. 99m Tc-Doxil showed slow blood clearance and no significant excretion from bowel and bladder.
99m Tc-Doxil also had a uniform high level of 99m Tcactivity in the intestine and surrounding abdominal tissues at 4, 20, and 44 h. In contrast, for 99m Tc-BMEDA alone, 99m Tc-activity was removed quickly from blood and excreted via bladder and digestive tract. Figure 5 shows the blood clearance curves of 99m Tc-Doxil labeled with 99m Tc-BMEDA and 99m Tc-BMEDA alone from baseline to 44 h. Exponential curve-fitting analysis of 99m TcDoxil blood clearance showed a two-phase blood clearance with 36.4% of the injected activity having a half-clearance time of 2.2 h and 63.7% of the injected activity having a half-clearance time of 26.2 h (n ϭ 5), which is similar to the reported blood clearance characteristics of Doxil (Gabizon et al., 2003) . In contrast, the unencapsulated 99m Tc-BMEDA had very rapid blood clearance, with 95.5% of the injected activity having a half-clearance time of only 0.12 h (n ϭ 4). Figure 6 shows the normal rat distribution of 99m Tc-Doxil labeled with 99m Tc-BMEDA and 99m Tc-BMEDA alone at 44 h after injection. At 44 h after injection, the 99m Tc activity mainly existed in blood, liver, bone with bone marrow, skin, bowel, and kidney with percentages of the injected doses of 19.8 Ϯ 1.3%, 14.1 Ϯ 1.7%, 9.0 Ϯ 0.8%, 6.0 Ϯ 0.5%, 15.3 Ϯ 4.3%, and 7.8 Ϯ 0.9%, respectively. Spleen, blood, liver, bone with bone marrow, skin, muscles, and bowel showed significantly higher percentages of 99m Tc activity per organ after injection of 99m Tc-Doxil compared with 99m Tc-BMEDA alone (P Ͻ 0.001). Rats also had significantly higher level of 99m TcDoxil in the bowel at 44 h after administration (P Ͻ 0.01). 99m Tc-BMEDA alone had significantly higher excretion from urine and feces (P Ͻ 0.01).
Discussion
In animal studies, 14 C labeled lipids or 3 H labeled cholesterol have been used to study the in vivo behavior of liposomes (Allen and Hansen, 1991; Unezaki et al., 1994) . The advantage of 14 C or 3 H labeling is that this labeling will not change the chemical structure of lipids, cholesterol, or drug molecules, because carbon and hydrogen atoms exist in the original molecules, and the isotope substitution will not change the in vivo behaviors of the labeled molecules. The major shortcoming of using 14 C or 3 H for in vivo behavior studies is that they are pure ␤ emitters and thus cannot be used to noninvasively detect the distribution in different tissues or organs in live animals using imaging. They also have long half-lives ( 14 C, 5730 years; 3 H, 12.33 years), so it is not feasible to use them in human subjects.
To achieve liposome labeling, radioisotopes can be attached to the surface of a liposome, intercalated into the double membrane of a liposome, or encapsulated within the inner space of a liposome (Hafeli et al., 1991) . To study the pharmacokinetics of liposomal therapeutic drugs indirectly by tracking the in vivo behavior of liposomes, an ideal labeling method is the direct radiolabeling of a liposome that is already loaded with drug molecules. This method would be the least likely to influence the in vivo behavior of liposomes that encapsulate therapeutic drugs. The direct radiolabeling of liposomes using an existing pH or ammonium gradient in liposomes carrying therapeutic drugs is convenient for the study of commercially available liposome formulations. To achieve this goal, a radiolabeled compound with certain lipophilicity is required for the compound to move across the lipophilic double membrane. Once in the liposome interior, the radiolabeled compound can be protonized in the lower pH environment of the inner space and be trapped. The 99m Tc-BMEDA complex we have studied is neutral and has certain lipophilicity at a higher pH environment.
99m Tc-BMEDA also contains amine groups, so it can be trapped within a liposome using a pH or ammonium gradient mechanism. These mechanisms enable the direct radiolabeling of the commercial Doxil with 99m Tc-BMEDA. Until now, no satisfactory method of directly labeling pH gradient or ammonium gradient liposomes encapsulating therapeutic drugs with 99m Tc has been reported. Another group has reported the direct labeling of liposomes using 99m Tc-diethylenetriaminepentaacetic acid, a very hydrophilic complex. The effectiveness of this labeling method and the correlated imaging studies are debatable (Laverman et al., 2002) . A reported Doxil direct labeling method using 
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111 In-oxine to label Doxil with 111 In was reported by Laverman et al. (2001 Laverman et al. ( , 2002 . By using this labeling method, gamma camera images up to 4 h after administration were reported; however, no information describing the labeling stability of this labeling method was reported.
Animal and human pharmacokinetic studies on Doxil showed that over 95% of doxorubicin stays trapped in liposomes in plasma (Gabizon et al., 2003) . This suggests the importance of clarifying the in vivo behavior of pegylated liposomes encapsulating therapeutic drugs. These pharmacokinetic studies demonstrated that the injected lipid amount will not influence the pharmacokinetics of pegylated liposomes if the injected lipids in the liposomes are less than 400 mol/kg (Allen and Hansen, 1991). The injected total lipid dose in our study was 46.3 mol/kg. Previous animal and human subject studies have shown that Doxil has a two-phase blood clearance with an initial-phase half-clearance time of 1 to 3 h and a second-phase half-clearance time of 30 to 90 h (Gabizon et al., 2003) . Our normal rat study showed a two-phase blood clearance pattern with a firstphase half-clearance time of 2.2 h and second-phase halfclearance time of 26.2 h (Fig. 5) . These normal rat distribution results of 99m Tc-Doxil labeled with 99m Tc-BMEDA are compatible with the data reported previously. In contrast, free 99m Tc-BMEDA has a very short blood half-clearance time of only 0.12 h.
The gamma camera images of 99m Tc-Doxil at different times in the current study depict the slow blood clearance and low level of excretion from bladder and digestive tract (Fig. 4) . In addition, 99m Tc-Doxil also accumulated in the intestine and the surrounding tissues, which is visible beginning 4 h after administration. The intestinal distribution of 99m Tc-Doxil is very different from the free 99m Tc-BMEDA, which had fast excretion from the bladder and digestive tract but did not distribute uniformly in the intestine and surrounding tissues. Normal rat distribution at 44 h showed that 99m Tc-Doxil has high levels of activity in blood, liver, bone with bone marrow, skin, and bowel. These results are also similar to the biodistribution of Doxil reported previously (Gabizon et al., 2003) . Comparisons between 99m TcDoxil labeled with 99m Tc-BMEDA and free 99m Tc-BMEDA showed that normal rats injected with 99m Tc-Doxil had significantly higher activity in blood, spleen, liver, bone with bone marrow, skin, muscle (P Ͻ 0.001 for all above organs), and bowel (P Ͻ 0.01). The relative high concentration of Doxil in skin and bowel may be related to the cutaneous and digestive system toxicities, such as mucositis and diarrhea, that have been reported in clinical trials (Androulakis et al., 2002; Syrigos et al., 2002; Tsavaris et al., 2002; Skubitz, 2003) . Because Doxil is a pegylated liposome, we observed less activity in the spleen compared with liposomes without polyethylene glycol (Bao et al., 2003a) .
The biodistribution showed no significant difference in kidney activity between 99m Tc-Doxil labeled with 99m Tc-BMEDA and free 99m Tc-BMEDA (P ϭ 0.075). This suggests that after 44 h, some of the 99m Tc-BMEDA released from metabolized liposomes accumulated in the kidney. Prior studies have established that liposomes do not distribute to any extent within the kidneys. This suggests that there is a need to be cautious when interpreting the biodistribution of the pegylated liposomes in kidney using the 99m Tc-liposomes labeled with 99m Tc-BMEDA, particularly in studies of greater than 4 h after administration when postmetabolism of 99m Tc-BMEDA begins to occur. Tumor-bearing animal and cancer patient studies showed that pegylated liposomes had significant localization in the tumors (Gabizon, 1992; Harrington et al., 2001) . The labeling of liposomes with 99m Tc-BMEDA has the potential for studying the tumor localization of a variety of pegylated liposomes encapsulating therapeutic drugs.
Imaging of the actual distribution of liposomes encapsulating drug molecules post-therapy could verify tumor drug delivery. A low liposome accumulation in the tumor of a particular patient may explain a lack of therapeutic response. The studies on the relationship between intratumoral Doxil concentration and treatment response would be beneficial to understand the pharmacokinetics of Doxil and to determine the proper Doxil dose to treat a tumor with good treatment response while lowering complications. In addition, the use of this imaging technique could also make it possible to observe possible increased immune responses by the liver and spleen, such as the increased Kupffer cell phagocytic activity (Daemen et al., 1995) .
This noninvasive imaging method may also be useful for studying the distribution of Doxil after an intervention aimed at increasing liposome accumulation in tumors. These interventions include focused hyperthermia, radiofrequency ablation, and radiation (Koukourakis et al., 2000; Matteucci et al., 2000; Monsky et al., 2002) . These physical modalities have been shown to increase liposome tumor accumulation by 2-to 10-fold following intravenous administration. This labeling method also makes it possible to study the tumor retention and distribution after direct intratumoral injection of 99m Tc-Doxil (Harrington et al., 2000c) . Another potential use of this methodology could be to label Doxil with therapeutic radionuclides for combined chemotherapy and radionuclide therapy. There are two therapeutic radionuclides, 186 Re and 188 Re, which belong to the same elemental group as technetium. Studies have shown that 99m Tc-"SNS/S" and Re-"SNS/S" complexes have the same coordinate structures (Pirmettis et al., 1996; Pelecanou et al., 1999) . In previous research, we have also demonstrated that ammonium gradient liposomes can also be labeled with 186 Re and 188 Re using 186 Re/ 188 Re-BMEDA (Bao et al., 2003b) .
